Clinical Diagnostics
The Precivity™ tests are innovative new blood tests intended for use in patients with cognitive impairment. These tests aim to help healthcare providers determine the presence or absence of amyloid plaques in the brain, a hallmark sign of Alzheimer’s disease, and aid in medical management and treatment decisions.
The PrecivityAD2™/PrecivityAD® blood tests are intended for use in patients aged 55 and older with signs or symptoms of mild cognitive impairment or dementia who are undergoing evaluation of Alzheimer’s disease or dementia.
The Precivity-ApoE™ blood test is indicated for use in adult patients for whom knowledge of apolipoprotein E2,E3,E4 allele status may be informative for medical management and treatment decisions.
Only a healthcare provider can order the Precivity™ tests.
The test is available in 49 states, the District of Columbia, and Puerto Rico; the exception is New York, which requires an individual state process for CLIA labs. C2N is working toward obtaining the requisite certification that will permit the PrecivityAD® test to be available in New York in the near future. Please periodically refer back to this website or contact C₂N at 1.877.C2N.DIAG (226.3424) for a status update on test availability in New York.
CLIA ID #: 26D2184292
Pipeline
The early manifestations of many neurological diseases, including memory disorders like Alzheimer’s disease (AD), are very difficult to accurately diagnose early in the course of disease. Early detection is necessary for early treatment and offering the best chances for delaying progression of disease. Given the importance of early detection and accurate diagnosis, C₂N is developing a comprehensive Brain Health Panel that will measure multiple features of AD and other neurological disorders. Tests in the pipeline include: core biomarkers for AD pathology (different forms of Aβ and tau): biomarkers for non-specific biomarkers in AD pathology and brain injury; and biomarkers for other non-AD pathologies responsible for other forms of neurological disease.